Nextage Therapeutics Stock Fundamentals
| NXTG Stock | ILA 67.70 1.70 2.45% |
Nextage Therapeutics fundamentals help investors to digest information that contributes to Nextage Therapeutics' financial success or failures. It also enables traders to predict the movement of Nextage Stock. The fundamental analysis module provides a way to measure Nextage Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nextage Therapeutics stock.
Nextage |
Nextage Therapeutics Company Return On Equity Analysis
Nextage Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nextage Therapeutics Return On Equity | -2.49 |
Most of Nextage Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nextage Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nextage Therapeutics has a Return On Equity of -2.4931. This is 89.6% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all Israel stocks is notably higher than that of the company.
Nextage Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nextage Therapeutics's current stock value. Our valuation model uses many indicators to compare Nextage Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nextage Therapeutics competition to find correlations between indicators driving Nextage Therapeutics's intrinsic value. More Info.Nextage Therapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nextage Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nextage Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nextage Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nextage Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nextage Therapeutics could also be used in its relative valuation, which is a method of valuing Nextage Therapeutics by comparing valuation metrics of similar companies.Nextage Therapeutics is currently under evaluation in return on equity category among its peers.
Nextage Fundamentals
| Return On Equity | -2.49 | |||
| Return On Asset | -0.79 | |||
| Operating Margin | 146.35 % | |||
| Current Valuation | 13.43 M | |||
| Shares Outstanding | 26.14 M | |||
| Shares Owned By Insiders | 82.36 % | |||
| Price To Book | 9.68 X | |||
| Price To Sales | 289.01 X | |||
| Revenue | 91 K | |||
| Gross Profit | 16 K | |||
| EBITDA | (7.58 M) | |||
| Net Income | (7.73 M) | |||
| Cash And Equivalents | 358 K | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.11 M | |||
| Current Ratio | 0.44 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (3.97 M) | |||
| Earnings Per Share | (0.30) X | |||
| Number Of Employees | 65 | |||
| Beta | 0.7 | |||
| Market Capitalization | 18.74 M | |||
| Total Asset | 4.27 M | |||
| Z Score | 6.3 | |||
| Net Asset | 4.27 M |
About Nextage Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nextage Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nextage Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nextage Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. NEXTAGE THERAPEUTI operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.